Prikaz osnovnih podataka o dokumentu

dc.creatorVujić, Zorica
dc.creatorMulavdić, Nedzad
dc.creatorSmajić, Miralem
dc.creatorBrborić, Jasmina
dc.creatorStanković, Predrag
dc.date.accessioned2019-09-02T11:29:01Z
dc.date.available2019-09-02T11:29:01Z
dc.date.issued2012
dc.identifier.issn1420-3049
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/1703
dc.description.abstractExperimental design method was used for HPLC determination of irbesartan and hydrochlorothiazide in combined dosage forms. The traditional approach for optimization of experiments is time-consuming, involves a large number of runs and does not allow establishing the multiple interacting parameters. The main advantages of the experimental design method include the simultaneous screening of a larger number of factors affecting response and the estimation of possible interactions. On the basis of preliminary experiments, three factors-independent variables were selected as inputs (methanol content, pH of the mobile phase and temperature) and as dependent variables, five responses (resolution, symmetry of irbesartan peak, symmetry of hydrochlorothiazide peak, retention factor of irbesartan and retention factor of hydrochlorothiazide) were chosen. A full 2(3) factorial design, where factors were examined at two different levels ("low" and "high") was used to determine which factors had an effect on the studied response. Afterwards, experimental design was used to optimize these influent parameters in the previously selected experimental domain. The novelty of our method lies in the optimization step accomplished by Derringer's desirability function. After optimizing the experimental conditions a separation was conducted on a Supelcosil C-18 (150 mm x 4.6 mm, 5 mu m particle size) column with a mobile phase consisting of methanol-tetrahydrofuran-acetate buffer 47:10:43 v/v/v, pH 6.5 and a column temperature of 25 degrees C. The developed method was successfully applied to the simultaneous separation of these drug-active compounds in their commercial pharmaceutical dosage forms.en
dc.publisherMDPI, Basel
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/172041/RS//
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceMolecules
dc.subjectHPLCen
dc.subjectexperimental designen
dc.subjectirbesartanen
dc.subjecthydrochlorothiazideen
dc.titleSimultaneous Analysis of Irbesartan and Hydrochlorothiazide: An Improved HPLC Method with the Aid of a Chemometric Protocolen
dc.typearticle
dc.rights.licenseBY
dcterms.abstractБрборић, Јасмина; Смајић, Миралем; Вујић, Зорица; Станковић, Предраг; Мулавдић, Недзад;
dc.citation.volume17
dc.citation.issue3
dc.citation.spage3461
dc.citation.epage3474
dc.citation.other17(3): 3461-3474
dc.citation.rankM22
dc.identifier.wos000302120600074
dc.identifier.doi10.3390/molecules17033461
dc.identifier.pmid22426527
dc.identifier.scopus2-s2.0-84858958219
dc.identifier.fulltexthttps://farfar.pharmacy.bg.ac.rs//bitstream/id/522/1701.pdf
dc.type.versionpublishedVersion


Dokumenti

Thumbnail

Ovaj dokument se pojavljuje u sledećim kolekcijama

Prikaz osnovnih podataka o dokumentu